Last reviewed 2026-04-23 · How we verify

SDR-PEP Rifampicin

SDR-PEP Rifampicin is a sustained-release formulation of rifampicin that inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis.

SDR-PEP Rifampicin is a sustained-release formulation of rifampicin that inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis. Used for Tuberculosis (pulmonary and extrapulmonary), Drug-resistant tuberculosis.

At a glance

Mechanism of action

Rifampicin is a well-established antibiotic that binds to bacterial RNA polymerase and blocks transcription, making it highly effective against Mycobacterium tuberculosis and other mycobacteria. The SDR-PEP (Solid Dispersion Rifampicin with Polyethylene Glycol) formulation is designed to improve bioavailability and provide sustained drug release, potentially enhancing therapeutic efficacy and reducing dosing frequency in tuberculosis treatment.

Approved indications

• Tuberculosis (pulmonary and extrapulmonary)
• Drug-resistant tuberculosis

Common side effects

• Hepatotoxicity
• Gastrointestinal disturbances
• Rash
• Drug interactions (enzyme induction)

Key clinical trials

• Novel Interventions and Diagnostic Tests for Leprosy (NA)
• Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) (PHASE2)
• Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• SDR-PEP Rifampicin CI brief — competitive landscape report
• SDR-PEP Rifampicin updates RSS · CI watch RSS
• Institute of Tropical Medicine, Belgium portfolio CI